Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
67.8M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
16.6M
-
Shares change
-
-3.26M
-
Total reported value, excl. options
-
$66.6M
-
Value change
-
-$11.8M
-
Number of buys
-
13
-
Number of sells
-
-19
-
Price
-
$4.01
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) as of Q3 2020
41 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2020.
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.6M shares
of 67.8M outstanding shares and own 24.51% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.77M shares), ADAMS STREET PARTNERS LLC (3.28M shares), BVF INC/IL (1.74M shares), Novo Holdings A/S (1.39M shares), RENAISSANCE TECHNOLOGIES LLC (875K shares), CHI Advisors LLC (583K shares), DIMENSIONAL FUND ADVISORS LP (436K shares), MILLENNIUM MANAGEMENT LLC (381K shares), BlackRock Inc. (162K shares), and ACADIAN ASSET MANAGEMENT LLC (157K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.